Previous 10 | Next 10 |
IGALMI™ (dexmedetomidine) commercial momentum accelerating with doubling of formulary wins, unlocking more than $55 million in targeted market opportunity, and an additional $255 million scheduled to vote Top-line data from pivotal SERENITY III Phase 3 trial (Part 1) for BXCL501 in...
2023-05-05 12:19:21 ET BioXcel Therapeutics ( NASDAQ: BTAI ) is scheduled to announce Q1 earnings results on Monday, May 8th, before market open. The consensus EPS Estimate is -$1.66 (-48.2% Y/Y) and the consensus Revenue Estimate is $0.32M Over the last 1 year, BTAI ...
NEW HAVEN, Conn., May 02, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that Vimal Mehta, Ph.D., CEO of BioXcel T...
2023-04-26 19:33:17 ET Summary We are reiterating the hold rating due to Igalmi launch uncertainties around market access and the limited commercial capacity of BTAI. Optimistic about upcoming Tranquility 2 and Serenity 3 trial readouts in 2Q23. Serenity 3 is considered fairly...
NEW HAVEN, Conn., April 24, 2023 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence approaches to develop transformative medicines in neuroscience and immuno-oncology, today announced that it will release its first quarter ...
2023-04-05 09:45:55 ET Summary Igalmi, an FDA-approved drug for agitation treatment in schizophrenia or bipolar disorder patients, faces unfavorable real-world prospects. Igalmi's $375,000 net revenue in 2022 disappointed, causing a 39% drop in BioXcel's stock value due to concern...
2023-03-16 18:45:17 ET Summary BioXcel Therapeutics, Inc. has just released results for the fourth quarter of 2022. Some analysts have expressed doubts about the commercial success of its Igalmi launch. The good growth in forms approved so far makes me very optimistic about th...
NEW HAVEN, Conn., March 14, 2023 (GLOBE NEWSWIRE) -- OnkosXcel Therapeutics, LLC (“OnkosXcel”) today announced that it has confidentially submitted a draft registration statement on Form S-1 with the Securities and Exchange Commission (the “SEC”) relating to the propos...
2023-03-10 07:50:25 ET After a ~13% decline in the previous session in reaction to the company's Q4 2022 results, BioXcel Therapeutics ( NASDAQ: BTAI ) continued to trade lower in the pre-market Friday as Jefferies downgraded it, citing an uncertain commercial outlook. The a...
2023-03-09 13:42:09 ET BioXcel Therapeutics, Inc. (BTAI) Q4 2022 Earnings Conference Call March 09, 2023 08:30 AM ET Company Participants Vimal Mehta - Chief Executive Officer & Founder Matt Wiley - Chief Commercial Officer Richard Steinhart - Chief Financial...
News, Short Squeeze, Breakout and More Instantly...
BioXcel Therapeutics Inc. Company Name:
BTAI Stock Symbol:
NASDAQ Market:
BioXcel Therapeutics Inc. Website:
Focused market-access strategy generates estimated net revenue of approximately $1.1 million, highest quarterly net revenue since commercial launch Represents 90% increase from the prior quarter and 141% increase from the second quarter of 2023 NEW HAVEN, Conn., July 16, 2024 (GLO...
Study achieved its objective and demonstrated no evidence of tachyphylaxis, tolerance, or withdrawal with 180 mcg dose (highest approved dose) For each episode occurring over seven days, a reduction in agitation was observed and no serious adverse events were reported following treatmen...
NEW HAVEN, Conn., May 28, 2024 (GLOBE NEWSWIRE) -- BioXcel Therapeutics, Inc. (Nasdaq: BTAI), a biopharmaceutical company utilizing artificial intelligence to develop transformative medicines in neuroscience and immuno-oncology, today announced that CEO Vimal Mehta, Ph.D., will present at the Jef...